BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)
CAPS Rating:
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Recs
GALNS data coming up soon and the eternal buyout hype should keep it going up